Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,264 Mln
P/E Ratio
--
P/B Ratio
4.35
Industry P/E
--
Debt to Equity
0
ROE
-0.39 %
ROCE
-38.42 %
Div. Yield
0 %
Book Value
11.2
EPS
-3.76
CFO
$-433.00 Mln
EBITDA
$-592.48 Mln
Net Profit
$-570.63 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Akero Therapeutics (AKRO)
| 47.38 | -9.05 | 56.61 | 102.37 | 59.00 | 16.02 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Akero Therapeutics (AKRO)
| 18.97 | -57.39 | 159.10 | -18.02 | 16.24 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects... against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Read more
President, CEO & Director
Dr. Andrew Cheng M.D., Ph.D.
President, CEO & Director
Dr. Andrew Cheng M.D., Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Akero Therapeutics Inc (AKRO) stood at $ 826 Mln as on 31-Dec-24
The share price of Akero Therapeutics Inc (AKRO) is $41.00 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Akero Therapeutics Inc (AKRO) has given a return of 59% in the last 3 years.
Akero Therapeutics Inc (AKRO) has a market capitalisation of $ 3,264 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Akero Therapeutics Inc (AKRO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Akero Therapeutics Inc (AKRO) and enter the required number of quantities and click on buy to purchase the shares of Akero Therapeutics Inc (AKRO).
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
The CEO & director of Dr. Andrew Cheng M.D., Ph.D.. is Akero Therapeutics Inc (AKRO), and CFO & Sr. VP is Dr. Andrew Cheng M.D., Ph.D..
There is no promoter pledging in Akero Therapeutics Inc (AKRO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Akero Therapeutics Inc. (AKRO) | Ratios |
|---|---|
|
Return on equity(%)
|
-39.22
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Akero Therapeutics Inc (AKRO) was $0 Mln.
$0.01
(
